153 related articles for article (PubMed ID: 35005460)
1. A case of sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic renal cell carcinoma.
Katagiri A; Yamazaki H; Ikeda T
IJU Case Rep; 2022 Jan; 5(1):15-18. PubMed ID: 35005460
[TBL] [Abstract][Full Text] [Related]
2. Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report.
Sagawa T; Sato Y; Nagashima H; Takada K; Takahashi M; Hirakawa M; Hamaguchi K; Tamura F; Fujikawa K; Okamoto K; Kawano Y; Sogabe M; Miyamoto H; Takayama T
Front Immunol; 2023; 14():1203621. PubMed ID: 37492584
[TBL] [Abstract][Full Text] [Related]
3. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
[TBL] [Abstract][Full Text] [Related]
4. Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report.
Shibata Y; Noguchi G; Suzuki T; Osaka K; Umemoto S; Kishida T
Am J Case Rep; 2021 Aug; 22():e932924. PubMed ID: 34358221
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
Chorti E; Kanaki T; Zimmer L; Hadaschik E; Ugurel S; Gratsias E; Roesch A; Bonella F; Wessendorf TE; Wälscher J; Theegarten D; Schadendorf D; Livingstone E
Eur J Cancer; 2020 May; 131():18-26. PubMed ID: 32248071
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
[TBL] [Abstract][Full Text] [Related]
7. Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma.
Segawa T; Motoshima T; Yatsuda J; Kurahashi R; Fukushima Y; Murakami Y; Yamaguchi T; Sugiyama Y; Yoshida R; Nakayama H; Kamba T
IJU Case Rep; 2023 Mar; 6(2):147-149. PubMed ID: 36874997
[TBL] [Abstract][Full Text] [Related]
8. Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.
Billon E; Walz J; Brunelle S; Thomassin J; Salem N; Guerin M; Vicier C; Dermeche S; Albiges L; Tantot F; Nenan S; Pignot G; Gravis G
Front Oncol; 2019; 9():1033. PubMed ID: 31649889
[No Abstract] [Full Text] [Related]
9. Sarcoidosis-like reaction induced by immune checkpoint inhibitor in a patient with hepatocellular carcinoma: a case report.
Torres-Zurita A; Vázquez-Montero L; Gallego-López L; Mediano-Rambla MD; de la Cruz-Merino L
Front Immunol; 2023; 14():1150128. PubMed ID: 37781378
[TBL] [Abstract][Full Text] [Related]
10. Safe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma.
Iwaki T; Niimi A; Kano M; Kurokawa Y; Yoshizaki U; Nozaki K; Nomiya A; Miyazaki H; Kume H
IJU Case Rep; 2021 Jan; 4(1):32-35. PubMed ID: 33426493
[TBL] [Abstract][Full Text] [Related]
11. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
12. Hyperprogressive Disease In a Metastatic Renal Cell Carcinoma Patient After Receiving Immune Checkpoint Inhibitors: A Case Report.
Alkader M; Altaha R; Alkhatib L; Jabali EH; Alsoreeky MS
Cureus; 2022 Oct; 14(10):e30194. PubMed ID: 36381823
[TBL] [Abstract][Full Text] [Related]
13. Two cases of delayed onset of immune-related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer.
Nakai Y; Otsuka T; Inoue T; Nawa T; Hatano K; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Nishimura K
IJU Case Rep; 2021 Sep; 4(5):326-329. PubMed ID: 34497995
[TBL] [Abstract][Full Text] [Related]
14. Seronegative rheumatoid arthritis after combination therapy with ipilimumab and nivolumab for postoperative pancreatic and liver metastases from renal cell carcinoma.
Nishimura Y; Yamanaka K; Kato T; Hatano K; Kawashima A; Fukuhara S; Uemura M; Imamura R; Nonomura N
IJU Case Rep; 2023 Mar; 6(2):101-105. PubMed ID: 36874995
[TBL] [Abstract][Full Text] [Related]
15. Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab.
Okada T; Hamamoto S; Etani T; Naiki T; Sue Y; Banno R; Yamada K; Sakakura T; Yasui T
Int Cancer Conf J; 2020 Apr; 9(2):88-91. PubMed ID: 32257760
[TBL] [Abstract][Full Text] [Related]
16. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature.
Reuss JE; Kunk PR; Stowman AM; Gru AA; Slingluff CL; Gaughan EM
J Immunother Cancer; 2016; 4():94. PubMed ID: 28031822
[TBL] [Abstract][Full Text] [Related]
17. Erythema Nodosum as the Initial Presentation of Nivolumab-Induced Sarcoidosis-Like Reaction.
Laroche A; Alarcon Chinchilla E; Bourgeault E; Doré MA
J Cutan Med Surg; 2018; 22(6):627-629. PubMed ID: 29772919
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitor-Associated Sarcoidosis Reaction in the Kidney: Case Report.
Charkviani M; Herrmann SM
Kidney Med; 2023 May; 5(5):100626. PubMed ID: 37122393
[TBL] [Abstract][Full Text] [Related]
19. [INTERSTITIAL NEPHRITIS CAUSED BY IPILIMUMAB AND NIVOLUMAB COMBINATION THERAPY FOR ADVANCED RENAL CELL CARCINOMA: A CASE REPORT].
Ishii M; Takezawa K; Imamura R; Fukuhara S; Fujita K; Uemura M; Kiuchi H; Nonomura N
Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):109-112. PubMed ID: 35444079
[TBL] [Abstract][Full Text] [Related]
20. Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation.
Kambe T; Yamasaki T; Mine Y; Hagimoto H; Kokubun H; Kubota M; Tsutsumi N; Inoue K; Hara S; Kawakita M
IJU Case Rep; 2022 May; 5(3):168-171. PubMed ID: 35509785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
